Pharmacoproteomics in cardiac hypertrophy and atherosclerosis.
Proteomics applications to study the molecular effects of drug administration (pharmacoproteomics) on left ventricular hypertrophy (LVH) and atherosclerosis are here reviewed. In most cases, an absence of complete normalization after treatment is revealed, in contrast to what is reported by classical approaches.
Lazaro
Alberto
A
Laboratory of Renal Physiopathology, Nephrology Department, Gregorio Marañón University General Hospital, Madrid, Spain.
Alvarez-Llamas
Gloria
G
Gallego-Delgado
Julio
J
de la Cuesta
Fernando
F
Osende
Julio
J
Barderas
M Eugenia G
ME
Vivanco
Fernando
F
D000959:Antihypertensive Agents / Q000627:therapeutic use; D050197:Atherosclerosis / Q000188:drug therapy* / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy* / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism; D020543:Proteome / Q000378:metabolism*; D040901:Proteomics
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D020543:Proteome